Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
Abstract Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aim...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Journal of Pharmaceutical Health Care and Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40780-022-00272-9 |
| _version_ | 1797845825844412416 |
|---|---|
| author | Shinya Tsuboi Tatsuya Hayama Katsuhiro Miura Akihiro Uchiike Daisuke Tsutsumi Takashi Yamauchi Yoshihiro Hatta Susumu Ootsuka |
| author_facet | Shinya Tsuboi Tatsuya Hayama Katsuhiro Miura Akihiro Uchiike Daisuke Tsutsumi Takashi Yamauchi Yoshihiro Hatta Susumu Ootsuka |
| author_sort | Shinya Tsuboi |
| collection | DOAJ |
| description | Abstract Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aimed to determine the risk factors for PIBP in real-world clinical practice. Main body We retrospectively collected the clinical records of patients who received pegfilgrastim to support myelosuppressive chemotherapy with at least a 10% risk of FN between 2015 and 2018 at our center. Patients received pegfilgrastim 3.6 mg between days 2 and 7 after chemotherapy administration (day 1) for primary or secondary prophylaxis against FN. All adverse events were recorded according to the Common Terminology Criteria for Adverse Events. Patients who experienced intermittent bone pain in the back, femur, or other anatomic sites after the pegfilgrastim administration were considered to have PIBP. To evaluate the relationship between PIBP incidence and patient characteristics, we performed univariate and multivariate logistic regression analyses to calculate the odds ratios (ORs) of possible risk factors for PIBP. We analyzed the data of 305 patients (median age: 63 years), who underwent 1220 chemotherapy cycles with pegfilgrastim per cycle. Univariate analysis revealed that female sex (vs. male sex), younger age (< 55 years vs. ≥ 55 years), and solid cancers (vs. hematologic cancers) had significantly higher ORs (p < 0.05). However, only younger age (< 55 years) was an independent risk factor for PIBP on multivariate analysis (OR 3.62, 95% confidence interval 1.51–8.69, p = 0.004). Conclusions Younger age (< 55 years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a ≥ 10% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim. |
| first_indexed | 2024-04-09T17:46:16Z |
| format | Article |
| id | doaj.art-971b7101717b4b708af2d32b96a7af91 |
| institution | Directory Open Access Journal |
| issn | 2055-0294 |
| language | English |
| last_indexed | 2024-04-09T17:46:16Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Pharmaceutical Health Care and Sciences |
| spelling | doaj.art-971b7101717b4b708af2d32b96a7af912023-04-16T11:20:34ZengBMCJournal of Pharmaceutical Health Care and Sciences2055-02942023-01-01911510.1186/s40780-022-00272-9Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experienceShinya Tsuboi0Tatsuya Hayama1Katsuhiro Miura2Akihiro Uchiike3Daisuke Tsutsumi4Takashi Yamauchi5Yoshihiro Hatta6Susumu Ootsuka7Department of Pharmacy, Nihon University Itabashi HospitalDepartment of Pharmacy, Nihon University Itabashi HospitalTumor Center, Nihon University Itabashi HospitalDepartment of Pharmacy, Nihon University Itabashi HospitalDepartment of Pharmacy, Nihon University Itabashi HospitalDepartment of Pharmacy, Nihon University Itabashi HospitalDepartment of Medicine, Division of Hematology and Rheumatology, Nihon University School of MedicineDepartment of Pharmacy, Nihon University Itabashi HospitalAbstract Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aimed to determine the risk factors for PIBP in real-world clinical practice. Main body We retrospectively collected the clinical records of patients who received pegfilgrastim to support myelosuppressive chemotherapy with at least a 10% risk of FN between 2015 and 2018 at our center. Patients received pegfilgrastim 3.6 mg between days 2 and 7 after chemotherapy administration (day 1) for primary or secondary prophylaxis against FN. All adverse events were recorded according to the Common Terminology Criteria for Adverse Events. Patients who experienced intermittent bone pain in the back, femur, or other anatomic sites after the pegfilgrastim administration were considered to have PIBP. To evaluate the relationship between PIBP incidence and patient characteristics, we performed univariate and multivariate logistic regression analyses to calculate the odds ratios (ORs) of possible risk factors for PIBP. We analyzed the data of 305 patients (median age: 63 years), who underwent 1220 chemotherapy cycles with pegfilgrastim per cycle. Univariate analysis revealed that female sex (vs. male sex), younger age (< 55 years vs. ≥ 55 years), and solid cancers (vs. hematologic cancers) had significantly higher ORs (p < 0.05). However, only younger age (< 55 years) was an independent risk factor for PIBP on multivariate analysis (OR 3.62, 95% confidence interval 1.51–8.69, p = 0.004). Conclusions Younger age (< 55 years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a ≥ 10% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim.https://doi.org/10.1186/s40780-022-00272-9AgeBone painChemotherapyFebrile neutropeniaPegfilgrastim |
| spellingShingle | Shinya Tsuboi Tatsuya Hayama Katsuhiro Miura Akihiro Uchiike Daisuke Tsutsumi Takashi Yamauchi Yoshihiro Hatta Susumu Ootsuka Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience Journal of Pharmaceutical Health Care and Sciences Age Bone pain Chemotherapy Febrile neutropenia Pegfilgrastim |
| title | Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience |
| title_full | Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience |
| title_fullStr | Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience |
| title_full_unstemmed | Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience |
| title_short | Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience |
| title_sort | higher incidence of pegfilgrastim induced bone pain in younger patients receiving myelosuppressive chemotherapy a real world experience |
| topic | Age Bone pain Chemotherapy Febrile neutropenia Pegfilgrastim |
| url | https://doi.org/10.1186/s40780-022-00272-9 |
| work_keys_str_mv | AT shinyatsuboi higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT tatsuyahayama higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT katsuhiromiura higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT akihirouchiike higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT daisuketsutsumi higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT takashiyamauchi higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT yoshihirohatta higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience AT susumuootsuka higherincidenceofpegfilgrastiminducedbonepaininyoungerpatientsreceivingmyelosuppressivechemotherapyarealworldexperience |